For more than 25 years, we have dedicated ourselves to developing, manufacturing and distributing hemostasis reagents. Our customers can always rely on us with scientific as well as practice-oriented issues. In cooperation with renowned international partners we constantly search for new paths.
Sarcura GmbH, a start-up company founded in November 2019, develops a machine platform for the industrial manufacturing of personalised cell therapeutics used in cancer treatment. Sarcura envisions to transform existing manufacturing paradigms by using semiconductor technology embedded in microfluidic liquid processing systems to bring bioprocess control to cellular level in order to scale global manufacturing capacity.
The AGRANA Research
bit.bio discovery combines single cell functional genomics with best-in-class cellular models to decipher complex cellular pathways and gain a better understanding of disease development. This next-generation CRISPR screening platform will help to understand the role of gene networks at unprecedented scale and resolution to discover and validate novel drug targets.
Myllia Biotechnology combines CRISPR screening with single-cell RNA sequencing, leveraging two transformative technologies to enable genetic screening for complex phenotypes. We utilize the CRISPR screening workflow to map the impact of thousands of genetic perturbations on the global transcriptome at single-cell resolution, thus effectively establishing a paradigm for next generation CRISPR screens.
Aposcience AG is unique in having developed a secretome-based regenerative therapy. The secretome is produced under GMP-conditions and was approved by the Austrian regulatory agency for a clinical phase II trial. Our product platform Aposec consists of two products: APO-1 - Aposec for internal diseases (acute myocardial infarction, spinal cord injury and stroke) APO-2 - Aposec for topical application (hard-healing wounds, diabetic ulcers)
YASARA Biosciences develops and distributes the YASARA molecular modelling and simulation program. This acronym stands for Yet Another Scientific Artificial Reality Application, and delineates the software's main purpose: to create an artificial reality inside the computer, atom by atom, visualize it in 3D and let the user interact with it. The focus has always been on biomolecular modelling, covering the most prominent topics (including structure prediction and docking).
Acticell is a research company that develops innovative solutions for new trends in the textile industry. The research and technology start-up has specialized in the field of cellulose chemistry, especially in the textile industry. Acticell know-how can replace life-threatening sandblasting and the environmentally harmful potassium permanganate in bleaching jeans. Worldwide leading jeans labels already rely on production processes with Acticell technology.
Brain Implant Therapeutics (BIT) Pharma was founded in November 2015 by leaders from academia and industry. The company resides in Graz, Austria. BIT Pharma develops and commercializes technologies for site-specific drug delivery to the central nervous system (CNS), in particular the brain, exploiting tailored drug delivery systems.
Ares Genetics is a sequencing service provider and bioinformatics developer revolutionizing how we address the global challenge of antimicrobial resistance (AMR). Ares Genetics enables better infection control and more targeted patient care by providing unprecedented insight into pathogens and AMR through next generation sequencing (NGS) and artificial intelligence (AI) powered solutions.
Microsynth Austria ist eine österreichische Tochtergesellschaft der Microsynth AG und befindet sich im Biotechnology Center Leberstrasse in Wien. Die Muttergesellschaft hat ihren Hauptsitz in Balgach, Schweiz, und betreibt weitere Tochtergesellschaften in Deutschland (Microsynth Seqlab) und der Schweiz (Ökogenik). Insgesamt beschäftigt Microsynth rund 100 Mitarbeiter.
NBS-C BioScience is a Contract Research Laboratory founded 2009 as a spin off by leading scientists of the Novartis Institutes for BioMedical Research in Vienna, Austria. In a second business field NBS-C BioScience develops and commercializes research tools and kit components for allergy research and diagnostics.
usePAT offers add-on devices for the improvement of in-line measurements in PAT (Process Analytical Technology) systems. They are compatible with a variety of sensors and can be designed and adapted to the specific needs and requirements of many fields of application. In order to facilitate the process of real-time measuring, our technology takes advantage of well-controlled ultrasonic fields for spatial particle manipulation in liquids.
Fresenius Kabi Austria, ist ein Tochterunternehmen des internationalen Gesundheitskonzerns Fresenius Kabi. Fresenius Kabi ist spezialisiert auf intravenös zu verabreichende generische Arzneimittel, Infusionstherapie und klinische Ernährung. Die Aktivitäten umfassen Entwicklung, Herstellung und Vertrieb von Produkten, die zur Verbesserung der Lebensqualität chronisch und kritisch kranker Patienten im Krankenhaus und im außerklinischen Bereich beitragen.
EURRUS Biotech GmbH ("Eurrus") is incorporated in Tulln, Austria. Founded in 2006 the existing partners joined in 2012. Development focus is Asthma with a newly developed API. Development status has reached CP IIb.
Core areas of expertise are design, development and production of real-time PCR-based tests for the detection of various pathogens such as bacteria, viruses, fungi and parasites, for applications in human and veterinary medicine.
Pregenerate GmbH is a Vienna- based medtech startup established in November, 2019 with an aim to improve treatment outcomes for osteoarthritis patients by in vitro monitoring of cellular responses to different therapeutics. The Pregenerate team consists of five full time employees with extensive academic and clinical experience, as well as years of expertise in the pharmaceutical industry.
enGenes Biotech develops customized solutions for the cost-effective production of recombinant proteins and plasmid DNA in microbial expression systems. The company’s unique, proprietary, E. coli-based enGenes-X-press technology platform achieves outstanding yields of soluble and active recombinant protein or plasmid DNA by reducing biological complexity. This is achieved by decoupling biomass growth from product formation.